Erythropoietin Stimulates Tumor Growth via EphB4

Sunila Pradeep; Jie Huang; Edna M. Mora; Alpa M. Nick; Min Soon Cho; Sherry Y. Wu; Kyunghee Noh; Chad V. Pecot; Rajesha Rupaimoole; Martin A. Stein; Stephan Brock; Yunfei Wen; Chiyi Xiong; Kshipra Gharpure; Jean M. Hansen; Archana S. Nagaraja; Rebecca A. Previs; Pablo Vivas-Mejia; Hee Dong Han; Wei Hu; Lingegowda S. Mangala; Behrouz Zand; Loren J. Stagg; John E. Ladbury; Bulent Ozpolat; S. Neslihan Alpay; Masato Nishimura; Rebecca L. Stone; Koji Matsuo; Guillermo N. Armaiz-Peña; Heather J. Dalton; Christopher Danes; Blake Goodman; Cristian Rodriguez-Aguayo; Carola Kruger; Armin Schneider; Shyon Haghpeykar; Padmavathi Jaladurgam; Mien Chie Hung; Robert L. Coleman; Jinsong Liu; Chun Li; Diana Urbauer; Gabriel Lopez-Berestein; David B. Jackson; Anil K. Sood

doi:10.1016/j.ccell.2015.09.008

Erythropoietin Stimulates Tumor Growth via EphB4

Sunila Pradeep, Jie Huang, Edna M. Mora, Alpa M. Nick, Min Soon Cho, Sherry Y. Wu, Kyunghee Noh, Chad V. Pecot, Rajesha Rupaimoole, Martin A. Stein, Stephan Brock, Yunfei Wen, Chiyi Xiong, Kshipra Gharpure, Jean M. Hansen, Archana S. Nagaraja, Rebecca A. Previs, Pablo Vivas-Mejia, Hee Dong Han, Wei HuLingegowda S. Mangala, Behrouz Zand, Loren J. Stagg, John E. Ladbury, Bulent Ozpolat, S. Neslihan Alpay, Masato Nishimura, Rebecca L. Stone, Koji Matsuo, Guillermo N. Armaiz-Peña, Heather J. Dalton, Christopher Danes, Blake Goodman, Cristian Rodriguez-Aguayo, Carola Kruger, Armin Schneider, Shyon Haghpeykar, Padmavathi Jaladurgam, Mien Chie Hung, Robert L. Coleman, Jinsong Liu, Chun Li, Diana Urbauer, Gabriel Lopez-Berestein, David B. Jackson, Anil K. Sood

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

Original language	English (US)
Pages (from-to)	610-622
Number of pages	13
Journal	Cancer cell
Volume	28
Issue number	5
DOIs	https://doi.org/10.1016/j.ccell.2015.09.008
State	Published - Nov 9 2015

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group
Flow Cytometry and Cellular Imaging Facility
Research Animal Support Facility

Access to Document

10.1016/j.ccell.2015.09.008

Cite this

Pradeep, S., Huang, J., Mora, E. M., Nick, A. M., Cho, M. S., Wu, S. Y., Noh, K., Pecot, C. V., Rupaimoole, R., Stein, M. A., Brock, S., Wen, Y., Xiong, C., Gharpure, K., Hansen, J. M., Nagaraja, A. S., Previs, R. A., Vivas-Mejia, P., Han, H. D., ... Sood, A. K. (2015). Erythropoietin Stimulates Tumor Growth via EphB4. Cancer cell, 28(5), 610-622. https://doi.org/10.1016/j.ccell.2015.09.008

Pradeep, S, Huang, J, Mora, EM, Nick, AM, Cho, MS, Wu, SY, Noh, K, Pecot, CV, Rupaimoole, R, Stein, MA, Brock, S, Wen, Y , Xiong, C, Gharpure, K, Hansen, JM, Nagaraja, AS, Previs, RA, Vivas-Mejia, P, Han, HD, Hu, W , Mangala, LS, Zand, B, Stagg, LJ, Ladbury, JE, Ozpolat, B, Alpay, SN, Nishimura, M, Stone, RL, Matsuo, K, Armaiz-Peña, GN, Dalton, HJ, Danes, C, Goodman, B, Rodriguez-Aguayo, C, Kruger, C, Schneider, A, Haghpeykar, S, Jaladurgam, P, Hung, MC, Coleman, RL, Liu, J , Li, C , Urbauer, D , Lopez-Berestein, G, Jackson, DB & Sood, AK 2015, 'Erythropoietin Stimulates Tumor Growth via EphB4', Cancer cell, vol. 28, no. 5, pp. 610-622. https://doi.org/10.1016/j.ccell.2015.09.008

@article{6088e9925c0349b19706a1d87b9dbe05,

title = "Erythropoietin Stimulates Tumor Growth via EphB4",

abstract = "While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.",

author = "Sunila Pradeep and Jie Huang and Mora, {Edna M.} and Nick, {Alpa M.} and Cho, {Min Soon} and Wu, {Sherry Y.} and Kyunghee Noh and Pecot, {Chad V.} and Rajesha Rupaimoole and Stein, {Martin A.} and Stephan Brock and Yunfei Wen and Chiyi Xiong and Kshipra Gharpure and Hansen, {Jean M.} and Nagaraja, {Archana S.} and Previs, {Rebecca A.} and Pablo Vivas-Mejia and Han, {Hee Dong} and Wei Hu and Mangala, {Lingegowda S.} and Behrouz Zand and Stagg, {Loren J.} and Ladbury, {John E.} and Bulent Ozpolat and Alpay, {S. Neslihan} and Masato Nishimura and Stone, {Rebecca L.} and Koji Matsuo and Armaiz-Pe{\~n}a, {Guillermo N.} and Dalton, {Heather J.} and Christopher Danes and Blake Goodman and Cristian Rodriguez-Aguayo and Carola Kruger and Armin Schneider and Shyon Haghpeykar and Padmavathi Jaladurgam and Hung, {Mien Chie} and Coleman, {Robert L.} and Jinsong Liu and Chun Li and Diana Urbauer and Gabriel Lopez-Berestein and Jackson, {David B.} and Sood, {Anil K.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = nov,

day = "9",

doi = "10.1016/j.ccell.2015.09.008",

language = "English (US)",

volume = "28",

pages = "610--622",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Erythropoietin Stimulates Tumor Growth via EphB4

AU - Pradeep, Sunila

AU - Huang, Jie

AU - Mora, Edna M.

AU - Nick, Alpa M.

AU - Cho, Min Soon

AU - Wu, Sherry Y.

AU - Noh, Kyunghee

AU - Pecot, Chad V.

AU - Rupaimoole, Rajesha

AU - Stein, Martin A.

AU - Brock, Stephan

AU - Wen, Yunfei

AU - Xiong, Chiyi

AU - Gharpure, Kshipra

AU - Hansen, Jean M.

AU - Nagaraja, Archana S.

AU - Previs, Rebecca A.

AU - Vivas-Mejia, Pablo

AU - Han, Hee Dong

AU - Hu, Wei

AU - Mangala, Lingegowda S.

AU - Zand, Behrouz

AU - Stagg, Loren J.

AU - Ladbury, John E.

AU - Ozpolat, Bulent

AU - Alpay, S. Neslihan

AU - Nishimura, Masato

AU - Stone, Rebecca L.

AU - Matsuo, Koji

AU - Armaiz-Peña, Guillermo N.

AU - Dalton, Heather J.

AU - Danes, Christopher

AU - Goodman, Blake

AU - Rodriguez-Aguayo, Cristian

AU - Kruger, Carola

AU - Schneider, Armin

AU - Haghpeykar, Shyon

AU - Jaladurgam, Padmavathi

AU - Hung, Mien Chie

AU - Coleman, Robert L.

AU - Liu, Jinsong

AU - Li, Chun

AU - Urbauer, Diana

AU - Lopez-Berestein, Gabriel

AU - Jackson, David B.

AU - Sood, Anil K.

PY - 2015/11/9

Y1 - 2015/11/9

N2 - While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

AB - While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

UR - http://www.scopus.com/inward/record.url?scp=84946552470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946552470&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.09.008

DO - 10.1016/j.ccell.2015.09.008

M3 - Article

C2 - 26481148

AN - SCOPUS:84946552470

SN - 1535-6108

VL - 28

SP - 610

EP - 622

JO - Cancer cell

JF - Cancer cell

IS - 5

ER -

Erythropoietin Stimulates Tumor Growth via EphB4

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this